CA3200710A1 - Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists - Google Patents
Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonistsInfo
- Publication number
- CA3200710A1 CA3200710A1 CA3200710A CA3200710A CA3200710A1 CA 3200710 A1 CA3200710 A1 CA 3200710A1 CA 3200710 A CA3200710 A CA 3200710A CA 3200710 A CA3200710 A CA 3200710A CA 3200710 A1 CA3200710 A1 CA 3200710A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- optionally substituted
- group
- heterocyclyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207719 | 2020-11-16 | ||
| EP20207719.4 | 2020-11-16 | ||
| PCT/EP2021/081459 WO2022101377A1 (en) | 2020-11-16 | 2021-11-12 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3200710A1 true CA3200710A1 (en) | 2022-05-19 |
Family
ID=73543025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3200710A Pending CA3200710A1 (en) | 2020-11-16 | 2021-11-12 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11766443B2 (https=) |
| EP (1) | EP4244229A1 (https=) |
| JP (2) | JP7465368B2 (https=) |
| KR (1) | KR20230109692A (https=) |
| CN (2) | CN116745300A (https=) |
| AR (1) | AR124070A1 (https=) |
| AU (1) | AU2021379248A1 (https=) |
| CA (1) | CA3200710A1 (https=) |
| CL (2) | CL2023001361A1 (https=) |
| CO (1) | CO2023005894A2 (https=) |
| CR (1) | CR20230211A (https=) |
| DO (1) | DOP2023000090A (https=) |
| EC (1) | ECSP23036210A (https=) |
| IL (1) | IL302769A (https=) |
| JO (1) | JOP20230107A1 (https=) |
| MX (1) | MX2023005678A (https=) |
| PE (1) | PE20231855A1 (https=) |
| SA (1) | SA523440809B1 (https=) |
| WO (1) | WO2022101377A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119842821A (zh) * | 2025-01-06 | 2025-04-18 | 华中科技大学 | 稳定表达血小板活化因子受体的细胞株、构建方法及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3502392A1 (de) | 1985-01-25 | 1986-07-31 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen |
| IE870123L (en) * | 1986-01-21 | 1987-07-21 | Boehringer Ingelheim Int | Thieno-1,4-diazepines |
| PH30676A (en) | 1986-07-22 | 1997-09-16 | Boehringer Ingelhein Kg | Hetrazepine compounds which have useful pharmaceutical utility |
| US4959361A (en) * | 1987-12-18 | 1990-09-25 | Hoffmann-La Roche Inc. | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists |
| MC1999A1 (fr) * | 1987-12-18 | 1990-01-26 | Hoffmann La Roche | Composes tricycliques |
| DE3909012A1 (de) | 1989-03-18 | 1990-09-20 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen |
| DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
| DE4132763A1 (de) | 1991-10-02 | 1993-04-08 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| US20050032713A1 (en) * | 2002-03-27 | 2005-02-10 | Wurtman Richard J. | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents |
| CA2670031A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
-
2021
- 2021-11-12 PE PE2023001605A patent/PE20231855A1/es unknown
- 2021-11-12 IL IL302769A patent/IL302769A/en unknown
- 2021-11-12 MX MX2023005678A patent/MX2023005678A/es unknown
- 2021-11-12 CN CN202180076849.5A patent/CN116745300A/zh active Pending
- 2021-11-12 AU AU2021379248A patent/AU2021379248A1/en active Pending
- 2021-11-12 CR CR20230211A patent/CR20230211A/es unknown
- 2021-11-12 EP EP21806745.2A patent/EP4244229A1/en active Pending
- 2021-11-12 KR KR1020237020295A patent/KR20230109692A/ko active Pending
- 2021-11-12 JP JP2022562298A patent/JP7465368B2/ja active Active
- 2021-11-12 CN CN202311341729.0A patent/CN117624188A/zh active Pending
- 2021-11-12 CA CA3200710A patent/CA3200710A1/en active Pending
- 2021-11-12 US US17/524,759 patent/US11766443B2/en active Active
- 2021-11-12 WO PCT/EP2021/081459 patent/WO2022101377A1/en not_active Ceased
- 2021-11-15 AR ARP210103159A patent/AR124070A1/es unknown
-
2023
- 2023-05-08 CO CONC2023/0005894A patent/CO2023005894A2/es unknown
- 2023-05-11 CL CL2023001361A patent/CL2023001361A1/es unknown
- 2023-05-11 DO DO2023000090A patent/DOP2023000090A/es unknown
- 2023-05-16 SA SA523440809A patent/SA523440809B1/ar unknown
- 2023-05-16 JO JOJO/P/2023/0107A patent/JOP20230107A1/ar unknown
- 2023-05-17 EC ECSENADI202336210A patent/ECSP23036210A/es unknown
- 2023-07-14 US US18/221,936 patent/US20230355638A1/en active Pending
-
2024
- 2024-02-01 CL CL2024000317A patent/CL2024000317A1/es unknown
- 2024-03-29 JP JP2024055696A patent/JP7810743B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN117624188A (zh) | 2024-03-01 |
| CR20230211A (es) | 2023-07-13 |
| CN116745300A (zh) | 2023-09-12 |
| US20220160725A1 (en) | 2022-05-26 |
| WO2022101377A1 (en) | 2022-05-19 |
| US20230355638A1 (en) | 2023-11-09 |
| CO2023005894A2 (es) | 2023-05-29 |
| ECSP23036210A (es) | 2023-06-30 |
| AR124070A1 (es) | 2023-02-08 |
| JP2024099528A (ja) | 2024-07-25 |
| KR20230109692A (ko) | 2023-07-20 |
| TW202237620A (zh) | 2022-10-01 |
| JP7465368B2 (ja) | 2024-04-10 |
| MX2023005678A (es) | 2023-05-26 |
| US11766443B2 (en) | 2023-09-26 |
| JP7810743B2 (ja) | 2026-02-03 |
| AU2021379248A9 (en) | 2024-10-10 |
| CL2024000317A1 (es) | 2024-07-12 |
| DOP2023000090A (es) | 2023-06-15 |
| JOP20230107A1 (ar) | 2023-05-16 |
| AU2021379248A1 (en) | 2023-06-22 |
| IL302769A (en) | 2023-07-01 |
| CL2023001361A1 (es) | 2023-11-03 |
| SA523440809B1 (ar) | 2024-10-08 |
| JP2023521200A (ja) | 2023-05-23 |
| PE20231855A1 (es) | 2023-11-21 |
| EP4244229A1 (en) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3210224A1 (en) | Cdk inhibitors and methods of use thereof | |
| TWI789381B (zh) | 雜環化合物 | |
| CA3120499A1 (en) | Glp-1r agonists and uses thereof | |
| TW201311688A (zh) | 四氫吡啶并－吡啶及四氫吡啶并－嘧啶化合物與其做為ｃ５ａ受體調節物之用途 | |
| WO2013052394A1 (en) | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors | |
| CA2960275A1 (en) | Smyd inhibitors | |
| TW202346289A (zh) | 作為ｇｌｐ—１ｒ促效劑的化合物 | |
| WO2014101295A2 (zh) | 一种詹纳斯激酶（JAKs）抑制活性的异恶唑衍生物 | |
| TW202021586A (zh) | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 | |
| TW202421130A (zh) | 作為pi3k抑制劑的異喹啉酮 | |
| AU2021218952A1 (en) | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | |
| JP7810743B2 (ja) | 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体 | |
| KR20250057699A (ko) | 신규한 par-2 억제제 | |
| CA3203922A1 (en) | Enzyme inhibitors | |
| EP3863713B1 (en) | Phenyltetrazole derivatives as plasma kallikrein inhibitors | |
| TWI913356B (zh) | 作為血小板活化因子受體拮抗劑之環戊烷并噻吩甲醯胺衍生物 | |
| US11992494B2 (en) | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | |
| EA048242B1 (ru) | Циклопентатиофенкарбоксамидные производные в качестве антагонистов рецептора фактора активации тромбоцитов | |
| WO2026042018A1 (en) | 4-{4-[(1-{[4-(propan-2-yl)phenyl]carbamoyl)-d-prolyl)amino]cyclohexyl}benzoic acid derivatives as gipr antagonists for the treatment of diabetes | |
| CA3172186A1 (en) | Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 | |
| HK1247918B (zh) | 用作irak1/4抑制剂的大环化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250815 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250815 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250815 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250819 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251008 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251008 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251008 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251008 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251008 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251103 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251103 |